Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and AD

Annals of NeurologyVolume 94, Issue 4 p. 618-619 Invited Commentary Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and AD Leslie M. Shaw PhD, Corresponding Author Leslie M. Shaw PhD [email protected] orcid.org/0000-0002-7650-1210 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Address correspondence to Dr Leslie M. Shaw, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. E-mail: [email protected]Search for more papers by this authorDouglas Galasko MD, Douglas Galasko MD Department of Neurosciences, University of California San Diego, La Jolla, CA, USASearch for more papers by this author Leslie M. Shaw PhD, Corresponding Author Leslie M. Shaw PhD [email protected] orcid.org/0000-0002-7650-1210 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Address correspondence to Dr Leslie M. Shaw, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. E-mail: [email protected]Search for more papers by this authorDouglas Galasko MD, Douglas Galasko MD Department of Neurosciences, University of California San Diego, La Jolla, CA, USASearch for more papers by this author First published: 24 August 2023 https://doi.org/10.1002/ana.26768 Authors contributed equally to this Commentary. Soldan A, et al. NPTX2 in cerebrospinal fluid predicts the progression from normal cognition to Mild Cognitive Impairment. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Buchave P, Minthon L, Zetterberg H, et al. Cerebrospinal fluid levels of β–amyloid 1-42 but not tau are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98–106. 2Van Harten AC, Wiste HJ, Weigand SD, et al. Detection of Alzheimer's disease amyloid beta 1-42, p-tau and t-tau assays. Alz Dementia 2022; 18: 635–644. 3Kaplow J, Vandijck M, Gray J, et al. Concordance of Lumipulse cerebrospinal fluid t-tau/A42 ratio with amyloid PET status. Alz Dementia 2020; 16: 144–152. 4Tosun D, Demir Z, Veitch DP, et al. Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's Dementia 2022; 18: 1370–1382. 5Masliah E, Mallory M, Alford M, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001; 56: 127–129. 6Camporesi E, Nilsson J, Brinkmalm A, et al. Fluid biomarkers for synaptic dysfunction and loss. Biomarker Insights 2020; 15. https://doi.org/10.1177/1177271920950319. 7Soldan A, Sungtaek O, Ryu T, et al. NPTX2 in cerebrospinal fluid predicts the progression from normal cognition to Mile Cognitive Impairment. Ann Neurol 2023; 94: 620–631. 8Spellman DS, Wildsmith KR, Honigberg LA, et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidatepeptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. Proteomics Clin Appl 2015; 9: 715–731. 9Swanson A, Willette AA, Alzheimer's Disease Neuroimaging Initiative. Neuronal Pentraxin2 predicts medial temporal atrophy and memory decline across the Alzheimer's disease spectrum. Brain Behav Immun 2016; 58: 202–208. 10Galasko D, Xiao M, Xu D, et al. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and AD. Alzheimers Dementia 2019; 5: 871–882. 11Libiger O, Shaw LM, Watson MH, et al. Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease. Alzheimer's Dementia 2021; 17: 1976–1987. 12Öhrfelt A, Benedet AL, Ashton NJ, et al. Association of CSF GAP-43 with the rate of cognitive decline and progression to dementia in amyloid-positive individuals. Neurology 2023; 100: e275–e285. https://doi.org/10.1212/WNL.0000000000201417. Volume94, Issue4October 2023Pages 618-619 ReferencesRelatedInformation